DavidPBenderMD

Obstetrics & Gynecology • Iowa City, IA

Gynecologic Oncology

Clinical Professor of Obstetrics & Gynecology, University Iowa College of Medicine

Join to view full profile

Dr. Bender is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bender's full profile

Already have an account?

Office
200 Hawkins Drive
Ste 100
Iowa City, IA 52242
Phone+1 319-356-1616

Fax+1 319-353-8363

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Gynecologic Oncology, 2001 - 2004
UPMC Medical EducationResidency, Obstetrics and Gynecology, 1995 - 1999
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1995

Certifications & Licensure

IA State Medical License 2000 - 2025
KY State Medical License 1999 - 2001
PA State Medical License 1996 - 2000
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28
Completed
Phase 1
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08
Active, not recruiting
Phase 2
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14
Completed
Phase 1
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 3
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Sexual Dysfunction in Gynecologic Oncology Patients Start of enrollment: 2019 Jun 06
Terminated
Phase 4
Roles: Contact, Sponsor-Investigator, Principal Investigator
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer Start of enrollment: 2021 Dec 31
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ova...
Jubilee Brown, Austin Miller, Laura L Holman, Floor Backes, Christa Nagel
Gynecologic Oncology. 2024-11-01
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/EN...
Bhavana Pothuri, Sileny Han, Dana M Chase, Florian Heitz, Robert A Burger
Gynecologic Oncology. 2024-05-01
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled...
Annika Auranen, Matthew A Powell, Vladyslav Sukhin, Lisa M Landrum, Graziana Ronzino
Therapeutic Advances in Medical Oncology. 2024-01-01

Press Mentions

University of Iowa Hospitals and Clinics' Pioneering Vision of Hospital Art Impacts HealingSeptember 26th, 2019